APMD apnimed announces FDA Acceptance of new drug application for ad109, an investigational oral pill to treat adults with obstructive Sleep
APMD apnimed announces FDA Acceptance of new drug application for ad109, an investigational oral pill to treat adults with obstructive Sleep apnea (osa) Apnimed - FDA sets pdufa target action date of February 28, 2027 for ad109 NDA - Ad109 generally well-tolerated in phase 3 trials with common adverse events dry mouth, insomnia, nausea
APMD apnimed announces FDA Acceptance of new drug application for ad109, an investigational oral pill to treat adults with obstructive Sleep apnea (osa) Apnimed - FDA sets pdufa target action date of February 28, 2027 for ad109 NDA - Ad109 generally well-tolerated in phase 3 trials with common adverse events dry mouth, insomnia, nausea